Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 197

1.

Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson's Disease.

Faust-Socher A, Duff-Canning S, Grabovsky A, Armstrong MJ, Rothberg B, Eslinger PJ, Meaney CA, Schneider RB, Tang-Wai DF, Fox SH, Zadikoff C, Kennedy N, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Reginold W, Marras C.

Dement Geriatr Cogn Disord. 2019;47(4-6):187-197. doi: 10.1159/000496454. Epub 2019 Jul 17.

PMID:
31315127
2.

Diagnostic delay in Parkinson's disease caused by PRKN mutations.

Ruiz-Lopez M, Freitas ME, Oliveira LM, Munhoz RP, Fox SH, Rohani M, Rogaeva E, Lang AE, Fasano A.

Parkinsonism Relat Disord. 2019 Jun;63:217-220. doi: 10.1016/j.parkreldis.2019.01.010. Epub 2019 Jan 10.

PMID:
30692050
3.

Update on treatments for nonmotor symptoms of Parkinson's disease-an evidence-based medicine review.

Seppi K, Ray Chaudhuri K, Coelho M, Fox SH, Katzenschlager R, Perez Lloret S, Weintraub D, Sampaio C; the collaborators of the Parkinson's Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee.

Mov Disord. 2019 Feb;34(2):180-198. doi: 10.1002/mds.27602. Epub 2019 Jan 17. Review. Erratum in: Mov Disord. 2019 May;34(5):765.

PMID:
30653247
4.

Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques.

Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR.

Mov Disord. 2019 May;34(5):708-716. doi: 10.1002/mds.27565. Epub 2018 Dec 21.

PMID:
30575996
5.

Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation.

Li MH, Mestre TA, Fox SH, Taati B.

J Neuroeng Rehabil. 2018 Nov 6;15(1):97. doi: 10.1186/s12984-018-0446-z.

6.

Th17 lymphocyte spearheads the immune attack in Parkinson's disease: New evidence for neuronal death.

Wagle Shukla A, Fox SH.

Mov Disord. 2018 Oct;33(10):1560. doi: 10.1002/mds.27496. No abstract available.

7.

Educational Needs and Considerations for a Visual Educational Tool to Discuss Parkinson's Disease.

Udow SJ, Hobson DE, Kleiner G, Masellis M, Fox SH, Lang AE, Marras C.

Mov Disord Clin Pract. 2017 Nov 27;5(1):66-74. doi: 10.1002/mdc3.12563. eCollection 2018 Jan-Feb.

8.

Levodopa-induced dyskinesia in Parkinson disease: Current and evolving concepts.

Espay AJ, Morgante F, Merola A, Fasano A, Marsili L, Fox SH, Bezard E, Picconi B, Calabresi P, Lang AE.

Ann Neurol. 2018 Dec;84(6):797-811. doi: 10.1002/ana.25364. Epub 2018 Nov 30. Review.

PMID:
30357892
9.

Viewpoint: Developing drugs for levodopa-induced dyskinesia in PD: Lessons learnt, what does the future hold?

Fox SH, Brotchie JM.

Eur J Neurosci. 2019 Feb;49(3):399-409. doi: 10.1111/ejn.14173. Epub 2018 Nov 15.

PMID:
30269407
10.

Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia.

Brigham EF, Johnston TH, Brown C, Holt JDS, Fox SH, Hill MP, Howson PA, Brotchie JM, Nguyen JT.

J Pharmacol Exp Ther. 2018 Nov;367(2):373-381. doi: 10.1124/jpet.118.247650. Epub 2018 Aug 7.

PMID:
30087157
11.

Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease.

Johnston TH, Lacoste AMB, Visanji NP, Lang AE, Fox SH, Brotchie JM.

Neuropharmacology. 2019 Mar 15;147:11-27. doi: 10.1016/j.neuropharm.2018.05.035. Epub 2018 Jun 1. Review.

PMID:
29907424
12.

Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features.

Li MH, Mestre TA, Fox SH, Taati B.

Parkinsonism Relat Disord. 2018 Aug;53:42-45. doi: 10.1016/j.parkreldis.2018.04.036. Epub 2018 May 5.

PMID:
29748112
13.

Update in therapeutic strategies for Parkinson's disease.

Kulisevsky J, Oliveira L, Fox SH.

Curr Opin Neurol. 2018 Aug;31(4):439-447. doi: 10.1097/WCO.0000000000000579. Review.

PMID:
29746402
14.

International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson's disease.

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C; Movement Disorder Society Evidence-Based Medicine Committee.

Mov Disord. 2018 Aug;33(8):1248-1266. doi: 10.1002/mds.27372. Epub 2018 Mar 23. Review. Erratum in: Mov Disord. 2018 Dec;33(12):1992.

PMID:
29570866
15.

Exacerbation of psychosis triggered by a synthetic cannabinoid in a 70-year-old woman with Parkinson disease.

Udow SJ, Freitas ME, Fox SH, Lang AE.

CMAJ. 2018 Jan 15;190(2):E50-E52. doi: 10.1503/cmaj.170361. No abstract available.

16.

Botulinum Toxin Type A for Pain in Advanced Parkinson's Disease.

Bruno V, Freitas ME, Mancini D, Lui JP, Miyasaki J, Fox SH.

Can J Neurol Sci. 2018 Jan;45(1):23-29. doi: 10.1017/cjn.2017.245.

PMID:
29334040
17.

DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.

Johnston TH, Versi E, Howson PA, Ravenscroft P, Fox SH, Hill MP, Reidenberg BE, Corey R, Brotchie JM.

Neuropharmacology. 2018 Mar 15;131:116-127. doi: 10.1016/j.neuropharm.2017.11.046. Epub 2017 Nov 29.

PMID:
29197517
18.

Automated vision-based analysis of levodopa-induced dyskinesia with deep learning.

Li MH, Mestre TA, Fox SH, Taati B.

Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:3377-3380. doi: 10.1109/EMBC.2017.8037580.

PMID:
29060621
19.

Motor Complications of Dopaminergic Medications in Parkinson's Disease.

Freitas ME, Hess CW, Fox SH.

Semin Neurol. 2017 Apr;37(2):147-157. doi: 10.1055/s-0037-1602423. Epub 2017 May 16. Review.

20.

Serotonergic Approaches in Parkinson's Disease: Translational Perspectives, an Update.

Huot P, Sgambato-Faure V, Fox SH, McCreary AC.

ACS Chem Neurosci. 2017 May 17;8(5):973-986. doi: 10.1021/acschemneuro.6b00440. Epub 2017 May 5. Review.

PMID:
28460160
21.

Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.

Fox SH, Metman LV, Nutt JG, Brodsky M, Factor SA, Lang AE, Pope LE, Knowles N, Siffert J.

Mov Disord. 2017 Jun;32(6):893-903. doi: 10.1002/mds.26976. Epub 2017 Mar 30.

PMID:
28370447
22.

The Relationship Between Serotonin-2A Receptor and Cognitive Functions in Nondemented Parkinson's Disease Patients with Visual Hallucinations.

Cho SS, Strafella AP, Duff-Canning S, Zurowski M, Vijverman AC, Bruno V, Aquino CC, Criaud M, Rusjan PM, Houle S, Fox SH.

Mov Disord Clin Pract. 2017 Jan 23;4(5):698-709. doi: 10.1002/mdc3.12466. eCollection 2017 Sep-Oct.

23.

Integrating Patient Concerns into Parkinson's Disease Management.

Lim SY, Tan AH, Fox SH, Evans AH, Low SC.

Curr Neurol Neurosci Rep. 2017 Jan;17(1):3. doi: 10.1007/s11910-017-0717-2. Review.

PMID:
28102483
24.

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations: A Randomized Clinical Trial.

Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R.

JAMA Neurol. 2017 Feb 1;74(2):216-224. doi: 10.1001/jamaneurol.2016.4467.

PMID:
27942720
25.

Epidermodysplasia verruciformis and the risk for malignancy.

Fox SH, Elston DM.

Cutis. 2016 Oct;98(4):E10-E12. No abstract available.

PMID:
27874888
26.

Novel Levodopa Formulations for Parkinson's Disease.

Freitas ME, Ruiz-Lopez M, Fox SH.

CNS Drugs. 2016 Nov;30(11):1079-1095. Review.

PMID:
27743318
27.

Clinical and demographic characteristics related to onset site and spread of cervical dystonia.

Norris SA, Jinnah HA, Espay AJ, Klein C, Brüggemann N, Barbano RL, Malaty IA, Rodriguez RL, Vidailhet M, Roze E, Reich SG, Berman BD, LeDoux MS, Richardson SP, Agarwal P, Mari Z, Ondo WG, Shih LC, Fox SH, Berardelli A, Testa CM, Cheng FC, Truong D, Nahab FB, Xie T, Hallett M, Rosen AR, Wright LJ, Perlmutter JS.

Mov Disord. 2016 Dec;31(12):1874-1882. doi: 10.1002/mds.26817. Epub 2016 Oct 18.

28.

Botulinum Toxin Use in Refractory Pain and Other Symptoms in Parkinsonism.

Bruno VA, Fox SH, Mancini D, Miyasaki JM.

Can J Neurol Sci. 2016 Sep;43(5):697-702. doi: 10.1017/cjn.2016.279. Epub 2016 Aug 12.

PMID:
27514242
29.

Erratum to: Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Chang A, Fox SH.

Drugs. 2016 Sep;76(13):1319. doi: 10.1007/s40265-016-0624-x. No abstract available.

PMID:
27503375
30.

Patient Management Problem-Preferred Responses.

Fox SH.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1327-36. doi: 10.1212/01.CON.0000491170.82888.0b. No abstract available.

PMID:
27495214
31.

Patient Management Problem.

Fox SH.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1321-6. doi: 10.1212/CON.0000000000000361. No abstract available.

PMID:
27495213
32.

Treating the Motor Symptoms of Parkinson Disease.

Morgan JC, Fox SH.

Continuum (Minneap Minn). 2016 Aug;22(4 Movement Disorders):1064-85. doi: 10.1212/CON.0000000000000355. Review.

PMID:
27495198
33.

Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Chang A, Fox SH.

Drugs. 2016 Jul;76(11):1093-118. doi: 10.1007/s40265-016-0600-5. Review. Erratum in: Drugs. 2016 Sep;76(13):1319. Dosage error in article text.

PMID:
27312429
34.

Nondopaminergic treatments for Parkinson's disease: current and future prospects.

Freitas ME, Fox SH.

Neurodegener Dis Manag. 2016 Jun;6(3):249-68. doi: 10.2217/nmt-2016-0005. Epub 2016 May 27. Review.

35.

Dopamine Reuptake Inhibitors in Parkinson's Disease: A Review of Nonhuman Primate Studies and Clinical Trials.

Huot P, Fox SH, Brotchie JM.

J Pharmacol Exp Ther. 2016 Jun;357(3):562-9. doi: 10.1124/jpet.116.232371. Epub 2016 Apr 13. Review.

PMID:
27190169
36.

Eligibility Criteria for Deep Brain Stimulation in Parkinson's Disease, Tremor, and Dystonia.

Munhoz RP, Picillo M, Fox SH, Bruno V, Panisset M, Honey CR, Fasano A.

Can J Neurol Sci. 2016 Jul;43(4):462-71. doi: 10.1017/cjn.2016.35. Epub 2016 May 3. Review.

PMID:
27139127
37.

Development of the Comprehensive Cervical Dystonia Rating Scale: Methodology.

Comella CL, Fox SH, Bhatia KP, Perlmutter JS, Jinnah HA, Zurowski M, McDonald WM, Marsh L, Rosen AR, Waliczek T, Wright LJ, Galpern WR, Stebbins GT.

Mov Disord Clin Pract. 2015 Jun;2(2):135-141. Epub 2015 Apr 6.

38.

Clinimetric testing of the comprehensive cervical dystonia rating scale.

Comella CL, Perlmutter JS, Jinnah HA, Waliczek TA, Rosen AR, Galpern WR, Adler CA, Barbano RL, Factor SA, Goetz CG, Jankovic J, Reich SG, Rodriguez RL, Severt WL, Zurowski M, Fox SH, Stebbins GT.

Mov Disord. 2016 Apr;31(4):563-9. doi: 10.1002/mds.26534. Epub 2016 Mar 12.

39.

Clozapine in Parkinsonian Rest Tremor: A Review of Outcomes, Adverse Reactions, and Possible Mechanisms of Action.

Yaw TK, Fox SH, Lang AE.

Mov Disord Clin Pract. 2015 Dec 30;3(2):116-124. doi: 10.1002/mdc3.12266. eCollection 2016 Mar-Apr. Review.

40.

Learning More from Finger Tapping in Parkinson's Disease: Up and Down from Dyskinesia to Bradykinesia.

Picillo M, Vincos GB, Kern DS, Fox SH, Lang AE, Fasano A.

Mov Disord Clin Pract. 2015 Oct 27;3(2):184-187. doi: 10.1002/mdc3.12246. eCollection 2016 Mar-Apr.

41.

What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?

Mestre TA, Beaulieu-Boire I, Aquino CC, Phielipp N, Poon YY, Lui JP, So J, Fox SH.

Parkinsonism Relat Disord. 2015 Nov;21(11):1349-54. doi: 10.1016/j.parkreldis.2015.09.044. Epub 2015 Sep 25.

PMID:
26439944
42.

Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.

Ma Y, Johnston TH, Peng S, Zuo C, Koprich JB, Fox SH, Guan Y, Eidelberg D, Brotchie JM.

Mov Disord. 2015 Aug;30(9):1283-8. doi: 10.1002/mds.26302.

43.

The highly-selective 5-HT(1A) agonist F15599 reduces L-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque.

Huot P, Johnston TH, Fox SH, Newman-Tancredi A, Brotchie JM.

Neuropharmacology. 2015 Oct;97:306-11. doi: 10.1016/j.neuropharm.2015.05.033. Epub 2015 Jun 10.

PMID:
26071982
44.

Placebo effect in Parkinson's disease: Harnessing the mind in the treatment of PD.

Udupa K, Fox SH.

Mov Disord. 2015 May;30(6):786. doi: 10.1002/mds.26222. Epub 2015 Apr 8. No abstract available.

PMID:
25855005
45.

Monoamine reuptake inhibitors in Parkinson's disease.

Huot P, Fox SH, Brotchie JM.

Parkinsons Dis. 2015;2015:609428. doi: 10.1155/2015/609428. Epub 2015 Feb 25. Review.

46.

The long-term outcome of orthostatic tremor.

Ganos C, Maugest L, Apartis E, Gasca-Salas C, Cáceres-Redondo MT, Erro R, Navalpotro-Gómez I, Batla A, Antelmi E, Degos B, Roze E, Welter ML, Mestre T, Palomar FJ, Isayama R, Chen R, Cordivari C, Mir P, Lang AE, Fox SH, Bhatia KP, Vidailhet M.

J Neurol Neurosurg Psychiatry. 2016 Feb;87(2):167-72. doi: 10.1136/jnnp-2014-309942. Epub 2015 Mar 13.

PMID:
25770124
47.

Orthostatic hypotension in Parkinsonism: What is it and how can we treat it?

Fox SH, Marras C.

Mov Disord. 2015 Apr 15;30(5):601-3. doi: 10.1002/mds.26179. Epub 2015 Mar 11. No abstract available.

PMID:
25764264
48.

Helicobacter pylori infection is associated with worse severity of Parkinson's disease.

Tan AH, Mahadeva S, Marras C, Thalha AM, Kiew CK, Yeat CM, Ng SW, Ang SP, Chow SK, Loke MF, Vadivelu JS, Ibrahim N, Yong HS, Tan CT, Fox SH, Lang AE, Lim SY.

Parkinsonism Relat Disord. 2015 Mar;21(3):221-5. doi: 10.1016/j.parkreldis.2014.12.009. Epub 2014 Dec 18.

PMID:
25560322
49.

Pioglitazone may impair L-DOPA anti-parkinsonian efficacy in the MPTP-lesioned macaque: results of a pilot study.

Huot P, Johnston TH, Fox SH, Brotchie JM.

Synapse. 2015 Mar;69(3):99-102. doi: 10.1002/syn.21801.

PMID:
25559284
50.

Tremor-Predominant Fragile X-Associated Tremor/Ataxia Syndrome in a Female.

Bruno V, Fox SH.

Mov Disord Clin Pract. 2014 Dec 30;2(1):45-46. doi: 10.1002/mdc3.12129. eCollection 2015 Mar. No abstract available.

Supplemental Content

Support Center